BIRMINGHAM, Ala., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Endomimetics, the developer of Bionanomatrix™, a peptide-based biomaterial to promote healing and improve outcomes following medical device implantation and other procedures, today announced the awarding of a $2.8 million Phase II Small Business Innovation Research (SBIR) grant to support research to evaluate the potential of Bionanomatrix™ to improve performance of flow diverters used in the treatment of brain aneurysms. This application of Bionanomatrix™ is one of several in development that provide further evidence of the broad utility of Bionanomatrix™ to improve performance and patient outcomes of implantable medical devices.
The Phase II SBIR grant provides funding to support research for (1) manufacturing process scale up and optimization including long term stability of the Bionanomatrix™ coating and packaging validation and (2) assessment of two- and six-month efficacy and safety of the Bionanomatrix™ coating in a rabbit aneurysm model. Under the grant, Endomimetics will collaborate with Ramanathan Kadirvel, Ph.D., and David Kallmes, M.D., both professors of Radiology at the Mayo Clinic, Rochester, Minnesota, to evaluate the Bionanomatrix™ coating for flow diverters in the brain.
"Brain aneurysms carry the devastating risk of rupture, leading to death or permanent disability," said Joseph Garner, Ph.D., Chief Executive Officer of Endomimetics. "Flow diverters, commonly used to treat aneurysms, maintain a risk of thromboembolic complications until endothelialization and aneurysm closure has occurred. ...
